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BACKGROUND The ﬁrst-in-class and most widely commercially
available bioresorbable scaffold (BRS) Absorb has strut thickness of
150 microns, far exceeding those of contemporary drug-eluting stents.
As such, it has potential for delivery challenges and higher thrombo-
genicity. As such, decreasing the BRS strut thickness with no adverse
effect on its biomechanics seems desirable. The aim of the study was
to assess safety and efﬁcacy of a novel thin strut (100 mm) sirolimus
eluting BRS (MeRes100, Meril Life Sciences, Gujarat, India) in porcine
coronary arteries.
METHODS A total of 34 coronary segments of 14 healthy swine were
implanted with 24 thin strut sirolimus eluting MeRes100 BRS and 10
Absorb scaffolds at 110% overstretch. To date, angiographic and op-
tical coherence tomography (OCT) imaging were performed after 1 and
3 months (MeRes100 n¼19 and Absorb n¼8 at each time point). Of the
entire cohort, 3 animals were euthanized at each time point and cor-
onary segments were harvested for histological evaluation.
RESULTS The animals in both groups were comparable with regard to
weight, clinical status, baseline vessel size and procedural character-
istics. All procedures were completed with no complications. At the
implantation procedure there was no statistical difference in angio-
graphic, minimal lumen diameter (MLD)-based percent acute recoil
between MeRes100 and Absorb (respectively: 13%  7% vs. 10%  5%
p¼0.18). OCT evaluation demonstrated no differences in metrics of
neointimal proliferation in MeRes100 when compared to Absorb at 1-
and 3-month follow up. Angiographic results corresponded to OCT
and showed similar results without statistical differences in MLD and
late loss at both time points. OCT and angiographic results are sum-
marized in the table. Histological analysis at 1-month follow up
revealed comparable results in MeRes100 and Absorb in % area ste-
nosis (respectively: 28.7  12.6% vs. 27.32.5% p¼0.86), neointimal
area (respectively 1.770.82 vs. 1.950.35 mm2; p¼0.22) and in qual-
itative parameters of vascular healing. Three-month histological re-
sults will be available by the time of the meeting.1 month 3 months
MeRes100 Absorb p MeRes100 Absorb p
A Minimal Lumen
Diameter(mm)
1.980.32 2.200.22 0.07 2.020.32 2.240.26 0.11
Late Loss(mm) 0.610.33 0.590.23 0.85 0.620.30 0.640.18 0.80
T % Area Stenosis 22.48.2 22.67.1 0.96 29.211.6 23.65.3 0.11
Neointimal
Thickness(mm)
0.170.06 0.170.05 0.86 0.220.10 0.180.04 0.86CONCLUSIONS The novel sirolimus-eluting BRS with thinner struts
and hybrid cell design showed similar radial strength and equivalent
inhibition of neointimal proliferation when compared to the bench-
mark Absorb BVS up to 90 days in normal porcine coronary arteries.
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BACKGROUND The J-CTO (Multicenter Chronic Total Occlusion [CTO]
Registry in Japan) score was developed to predict the probability of
successful guidewire crossing within 30 minutes. However, guidewire
crossing alone does not ensure ﬁnal success of CTO PCI. We therefore
sought to develop a novel parsimonious scoring system to estimate
the likelihood of technical success.
METHODS We examined 781 CTO percutaneous coronary in-
terventions (PCI) performed using the “hybrid” approach and
included in the Prospective Global Registry for the Study of Chronic
Total Occlusion Intervention (PROGRESS CTO). To develop the
“PROGRESS CTO” score we analyzed clinical and angiographic pa-
rameters using a derivation and validation cohort (2:1 sampling ratio).
Variables with strong association with technical failure in multivari-
able analysis were assigned 1 point and a 4-point score was developed
from summing all points. The PROGRESS CTO score was subsequently
compared with the J-CTO score in the validation cohort.
RESULTS Technical success was achieved in 726 lesions (92.9%).
Factors associated with technical success on multivariable analysis
included proximal cap ambiguity (beta coefﬁcient b¼0.88), moderate/
severe tortuosity (b¼1.18), left circumﬂex artery CTO PCI (b¼0.99),
and absence of “interventional” collaterals (b¼0.88). The resulting
PROGRESS CTO score demonstrated good calibration and discrimi-
natory capacity in the derivation (Hosmer-Lemeshow c2¼2.633,
p¼0.268 and receiver operator characteristic [ROC] area¼0.778) and
validation subset (Hosmer-Lemeshow c2¼5.333, p¼0.070 and ROC
area¼0.720). In the validation cohort, the PROGRESS CTO and J-CTO
performed similarly in predicting ﬁnal procedural success and
guidewire crossing at 30 minutes, respectively (ROC area 0.720 vs.
0.746, area under the curve AUC difference¼0.026, 95% conﬁdence
interval¼-0.093 to 0.144).
CONCLUSIONS The PROGRESS CTO score is a novel useful tool for
estimating technical success in CTO PCI performed using the hybrid
approach.
